Test Code PCHE1 Pseudocholinesterase, Total, Serum
Necessary Information
Patient's age and sex are required.
Specimen Required
Patient Preparation: For patients with prolonged apnea following surgery, wait at least 24 hours before obtaining specimen.
Supplies: Sarstedt Aliquot Tube, 5 mL (T914)
Collection Container/Tube:
Preferred: Serum gel
Acceptable: Red top
Submission Container/Tube: Plastic vial
Specimen Volume: 0.5 mL
Collection Instructions:
1. Serum gel tubes should be centrifuged within 2 hours of collection.
2. Red-top tubes should be centrifuged, and the serum aliquoted into a plastic vial within 2 hours of collection.
Useful For
Monitoring exposure to organophosphorus insecticides and herbicides
Monitoring patients with liver disease, particularly those undergoing liver transplantation
Identifying patients who are homozygous or heterozygous for an atypical gene and have low levels of pseudocholinesterase
This test is not useful for the differential diagnosis of jaundice.
Method Name
Colorimetric Assay
Reporting Name
Pseudocholinesterase, Total, SSpecimen Type
SerumSpecimen Minimum Volume
0.25 mL
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Serum | Refrigerated (preferred) | 14 days | |
Frozen | 365 days | ||
Ambient | 24 hours |
Reference Values
Males
5320-12,920 U/L
Females
0-15 years: 5320-12,920 U/L
16-39 years: 4260-11,250 U/L
40-41 years: 5320-12,920 U/L
≥42 years: 5320-12,920 U/L
Note: Females aged 18-41 years who are pregnant or taking hormonal contraceptives, the reference interval is 3650-9120 U/L.
Interpretation
Patients with normal pseudocholinesterase (PCHE) activity show 70% to 90% inhibition by dibucaine, while patients homozygous for the abnormal allele show little or no inhibition (0%-20%) and usually low levels of enzyme.
Heterozygous patients have intermediate PCHE levels and response to inhibitors.
The atypical gene is inherited in an autosomal recessive pattern. In a positive patient, family members should be tested.
Decreasing or low levels may indicate exposure to organophosphorus insecticides or herbicides if liver disease and an abnormal allele have been ruled out.
Clinical Reference
1. Soliday FK, Conley YP, Henker R. Pseudocholinesterase deficiency: A comprehensive review of genetic, acquired, and drug influences. AANA J. 2010;78:313-320
2. Robles A, Michael M, McCallum R. Pseudocholinesterase deficiency: What the proceduralist needs to know. Am J Med Sci. 2019;357(3):263-267. doi:10.1016/j.amjms.2018.11.002
3. Lurati AR. Organophosphate exposure with pseudocholinesterase deficiency. Workplace Health and Saf. 2013;61(6):243-245. doi:10.1177/216507991306100602
4. den Blaauwen DH, Poppe WA, Tritschler W. Cholinesterase (EC 3.1.1.8) with butyrylthiocholine-iodide as substrate: References depending on age and sex with special reference to hormonal effects and pregnancy. J Clin Chem Clin Biochem. 1983;21:381-386
Day(s) Performed
Monday through Friday
Report Available
Same day/1 to 3 daysPerforming Laboratory
Mayo Clinic Laboratories in RochesterTest Classification
This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.CPT Code Information
82480
LOINC Code Information
Test ID | Test Order Name | Order LOINC Value |
---|---|---|
PCHE1 | Pseudocholinesterase, Total, S | 2098-2 |
Result ID | Test Result Name | Result LOINC Value |
---|---|---|
PCHE1 | Pseudocholinesterase, Total, S | 2098-2 |